0.05 USD
-0.02 (-27.54%)
0.0517 USD
+0 (+3.4%)
SXTC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. SXTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SXTC has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- SXTC had negative earnings in the past year.
- SXTC had a negative operating cash flow in the past year.
- In the past 5 years SXTC always reported negative net income.
- In the past 5 years SXTC reported 4 times negative operating cash flow.
1.2 Ratios
- SXTC's Return On Assets of -15.25% is fine compared to the rest of the industry. SXTC outperforms 61.58% of its industry peers.
- With a decent Return On Equity value of -21.40%, SXTC is doing good in the industry, outperforming 65.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.25% | ||
| ROE | -21.4% | ||
| ROIC | N/A |
ROA(3y)-16.24%
ROA(5y)-14.76%
ROE(3y)-28%
ROE(5y)-27.24%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- SXTC's Gross Margin of 21.11% is in line compared to the rest of the industry. SXTC outperforms 53.68% of its industry peers.
- SXTC's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for SXTC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-16.61%
2. Health
2.1 Basic Checks
- SXTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for SXTC has been increased compared to 1 year ago.
- The number of shares outstanding for SXTC has been increased compared to 5 years ago.
- The debt/assets ratio for SXTC has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -0.73, we must say that SXTC is in the distress zone and has some risk of bankruptcy.
- SXTC has a Altman-Z score (-0.73) which is in line with its industry peers.
- A Debt/Equity ratio of 0.05 indicates that SXTC is not too dependend on debt financing.
- SXTC has a Debt to Equity ratio (0.05) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.73 |
ROIC/WACCN/A
WACC7.43%
2.3 Liquidity
- A Current Ratio of 3.54 indicates that SXTC has no problem at all paying its short term obligations.
- The Current ratio of SXTC (3.54) is comparable to the rest of the industry.
- SXTC has a Quick Ratio of 3.40. This indicates that SXTC is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 3.40, SXTC perfoms like the industry average, outperforming 57.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.4 |
3. Growth
3.1 Past
- SXTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.31%, which is quite impressive.
- The Revenue has decreased by -9.73% in the past year.
- SXTC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -19.53% yearly.
EPS 1Y (TTM)97.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.39%
Revenue 1Y (TTM)-9.73%
Revenue growth 3Y-12.51%
Revenue growth 5Y-19.53%
Sales Q2Q%-7.84%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- SXTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for SXTC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CHINA SXT PHARMACEUTICALS IN / SXTC FAQ
What is the ChartMill fundamental rating of CHINA SXT PHARMACEUTICALS IN (SXTC) stock?
ChartMill assigns a fundamental rating of 1 / 10 to SXTC.
What is the valuation status for SXTC stock?
ChartMill assigns a valuation rating of 0 / 10 to CHINA SXT PHARMACEUTICALS IN (SXTC). This can be considered as Overvalued.
What is the profitability of SXTC stock?
CHINA SXT PHARMACEUTICALS IN (SXTC) has a profitability rating of 1 / 10.